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Abstract
Introduction: Monocarboxylate transporters (MCTs) 1–4 are lactate transporters crucial for cancers cells adaption to
upregulated glycolysis. Herein, we aimed to explore their prognostic impact on disease-specific survival (DSS) in both cancer
and tumor stromal cells in NSCLC.
Methods: Tissue micro arrays (TMAs) were constructed, representing both cancer and stromal tumor tissue from 335
unselected patients diagnosed with stage I–IIIA NSCLC. Immunohistochemistry was used to evaluate the expression of
MCT1-4.
Results: In univariate analyses; QMCT1 (P = 0.021) and qMCT4 (P = 0.027) expression in cancer cells, and qMCT1
(P = 0.003), QMCT2 (P = 0.006), QMCT3 (P = 0.020) expression in stromal cells correlated significantly with a poor DSS. In
multivariate analyses; QMCT1 expression in cancer cells (HR: 1.9, CI 95%: 1.3–2.8, P = 0.001), QMCT2 (HR: 2.4, CI 95%: 1.5–
3.9, P,0.001), QMCT3 (HR: 1.9, CI 95%: 1.1–3.5, P = 0.031) and qMCT1 expression in stromal cells (HR: 1.7, CI 95%: 1.1–2.7,
P = 0.016) were significant independent poor prognostic markers for DSS.
Conclusions: We provide novel information of MCT1 as a candidate marker for prognostic stratification in NSCLC.
Interestingly, MCT1 shows diverging, independent prognostic impact in the cancer cell and stromal cell compartments.
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Introduction
Non-small cell lung cancer (NSCLC) is a major cause of cancer
deaths in the Western World, with a 5-year survival still as low as
16% in the United States [1]. The latter is due to late symptoms
and lack of early detection measures. New and better predictive
and prognostic markers in NSCLC are highly warranted.
Hypoxia is a common feature of solid tumors [2], and our
research group has previously published articles on hypoxic
markers in NSCLC [3–6]. A necessary metabolic adaption to
hypoxia is a switch to energy generation by glycolysis. In addition,
malignant cells in general even seem to prefer glycolysis despite the
presence of oxygen (‘‘Warburg effect’’) [7]. The cancer cells’
ability to switch to glycolysis is believed to represent a growth
advantage, since the oxygen availability in a tumor can fluctuate
over time [8]. However, glycolysis also increases lactic acid
production. To avoid intracellular acidification and apoptosis,
glycolytic cells must sustain lactate homeostasis. Several trans-
porters are involved in this process including monocarboxylate
transporters (MCT) 1–4 [9]. MCT1-4 are trans-membrane
symporters involved in lactate and pyruvate transportation.
MCT1 and MCT4 are located in the cell membrane. MCT4
exports lactate, while MCT1 can facilitate both import and export
depending on the pH gradient [10]. The potential roles of MCT2
and MCT3 in cancers are less studied. MCT2 is reported to be
expressed in the mitochondrial membrane, where it is involved in
the import of pyruvate following lactate oxidation [11]. MCT3
export lactate, but is only reported to be expressed in retinal
pigment epithelium and choroid plexus epithelium [9]. Lactate
homeostasis can also be sustained through metabolic co-operation
between cancer cells and tumor stroma cells [11,12]. This theory
of metabolic co-operation is based on the observation that cancer
cells express proteins involved in anaerobic glycolysis (like
GLUT1), while stromal cells express complementary proteins
involved in lactate oxidation.
Although energy metabolism has been a rather unexploited field
in cancer treatment, effectors of energy metabolism are intriguing
targets of therapy [13]. The expression of MCTs and their
functional role in normal tissue is well characterized, but the
transporter expression and role in different cancers has just
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recently started to be investigated [9]. Due to the recent
observation that MCTs may play a central part in tumor biology,
and that MCT1 is considered as a potential target in cancer
treatment, we aimed to explore the prognostic impact of MCT1–4
on disease specific survival (DSS) in both cancer and tumor
stromal cells from NSCLC patients. In addition, we investigated




The Norwegian Data Inspectorate and The Regional Commit-
tee for Medical and Health Research Ethics Nord (Nordland,
Troms and Finnmark) have approved the study. Patient records/
information was anonymized and de-identified prior to analysis.
The need for consent was specifically waived by The Regional
Committee for Research Ethics, since the study was retrospective
with more than half of the patients deceased.
Patients
Primary tumor tissue samples from 371 patients diagnosed with
NSCLC stage I-IIIA at the University Hospital of Northern
Norway and Nordland Central Hospital from 1990 to 2004 were
collected retrospectively. Thirty-six patients were excluded from
the cohort. Exclusion from the study was due to radiotherapy or
chemotherapy prior to surgery (n = 10), other malignancy within
the 5 years prior to diagnosis (n = 13) or inadequate paraffin-
embedded fixed tissue blocks (n = 13). A representative cohort of
335 patients was included in the study, and complete demographic
and clinicopathological data were obtained retrospectively. An
anonymised database was established. Staging of the tumors was
done according to the World Health Organization Guidelines
[14]. Two experienced pathologists reviewed all primary tissue
carefully prior to the study (S.A.S. and K.A.S).
Microarray construction
The most representative areas of cancer cells and tumor stromal
cells were identified. Using a tissue-arraying instrument (Beecher
Instruments, Silver Springs, MD), two representative 0.6 mm core
biopsies of cancer cells and two representative 0.6 mm core
biopsies of tumor stromal cells were collected from each surgical
specimen. As controls, normal lung tissue localized distant from
the primary tumor was used in addition to samples from 20
normal lungs. All the cores were gathered in eight tissue
microarray blocks (TMAs). Detailed methodology has been
reported previously [15].
Immunohistochemistry
All applied antibodies had been subjected to validation by the
manufacturer for immunohistochemistry (IHC) on paraffin-
embedded material, in addition MCT1 and MCT4 was validated
by in-house Western blot analysis (Figure 1). All sections were
deparaffinised with xylene and rehydrated with ethanol. The 4 mm
sections containing tissue cores were subjected to the following
antibodies: MCT1 (rabbit polyclonal, AB3538P, Millipore, 1/75),
MCT2 (goat polyclonal, ab129290, Abcam, 1:150), MCT3 (rabbit
polyclonal, ab60333, Abcam, 1:50), MCT4 (rabbit polyclonal, sc-
50329, Santa Cruz, 1:200) and GLUT1 (mouse monoclonal,
AB40084, Abcam; 1:500) [5].
MCT1 and MCT4 were stained using the Ventana Benchmark
XT (Ventana Medical Systems Inc.) procedure ultraview DAB.
Antigen retrieval was done automatic by CC1 mild (32 min).
For MCT2 and MCT3, antigen retrieval was done manually by
placing the specimens in 0.01 M citrate buffer at pH 6.0 and
exposed to microwave heating of 20 minutes at 450 W. The
primary antibody was visualized by adding a secondary antibody
conjugated with Biotin, followed by an Avidin/Biotin/Peroxydase
complex (Vectastein ABC Elite kit from Vector Laboratories).
Finally, all slides were counterstained with hematoxylin to visualize
the nuclei.
Scoring of immunohistochemistry
Scoring was done using light microscopy, and performed
independently and semi-quantitatively by one experienced pathol-
ogist (S.A.S) and one M.D (M.E). Both intensity and density was
scored when possible. The dominant staining intensity in cores of
cancer cells and stromal cells was scored as; 0 = negative, 1 = weak,
2 = intermediate, 3 = strong (Figure 2). Staining density was scored
as 0 = none, 1 = 1–10%, 2 = 11–50%, 3 = 51–100%. In case of
disagreement, slides were re-examined and consensus was reached
by the observers. Inter-individual variability in IHC-scoring in
both cancer cells and stromal cells was evaluated on the current
material.
Mean scores for cancer cell cores and stromal cell cores were
calculated. In cancer cells, high expression was defined as: .1.5
for MCT1 and MCT3; .1 for MCT2; .2 for MCT4. Density
was used for MCT1 and MCT4 in cancer cells, while MCT2 and
MCT3 cancer cells intensity scores were used. In stromal cells,
high expression was defined as: .1 for MCT1 and MCT3; .1.5
for MCT2 and MCT4. For MCT1 and MCT2 stroma intensity
scores were used. For MCT3 and MCT4 stroma density scores
were used. The same IHC scoring method has been utilized in
previous studies from our group [15].
Furthermore, we constructed four co-expression variables. The
first co-expression variable was created to test the potential
synergistic impact when both GLUT1 (glucose import) [5] and
Figure 1. Western Blot of MCT1 and MCT4. In all cell lines
investigated (A-549; lung adenocarcinoma, H661; large cell carcinoma,
U-251 MG; neuronal glioblastoma) a protein band of approximately
40 kDa was detected corresponding to MCT1 and MCT4. Equal loading
was ensured by B-actin.
doi:10.1371/journal.pone.0105038.g001
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MCT4 (lactate export) is expressed in cancer cells; GLUT1c+
MCT4c. The other three co-expression variables assessed the
hypothesized synergetic effect of metabolic co-operation between
cancer cells and stromal cells; GLUT1c+MCT1 (lactate import)s,
MCT4c+MCT1s and MCT1c+MCT4s. Kaplan Meier curves of
the co-expression variables were made with the following
stratifications low/low, other (low/high or high/low), high/high.
Western blot
Cell lysates were incubated with NuPAGE LDS Sample Buffer
(Life Technologies, USA) for 5 minutes at 85uC, sonicated briefly
and run on a NuPAGE 4–12% Bis Tris Gel (Life Technologies,
USA). Blotting was performed onto a Hybond nitrocellulose
membrane (GE Healthcare) using the NuPAGE blotting system
(Life Technologies, USA). The membrane was incubated with
Odyssey blocking buffer (LI-COR Biosciences, Germany) for
1 hour at room temperature. Primary and secondary antibodies
were diluted in the blocking buffer. Anti-MCT1 antibody
(Millipore, USA, cat#AB3538p) was used in the dilution of
1:500, anti-MCT4 in the dilution 1:500 (Santa Cruz, USA,
cat#SC-50329) and anti-actin (Sigma, cat#A2066) 1:2000.
IRDye CW secondary antibodies (LI-COR, Germany) were used
in dilution 1:10000. Molecular weight markers used were SeeBlue
Plus 2 (Life Technologies, USA, cat#LC5925) and Magic Mark
XP (Life Technologies, USA, cat#LC5602). Images were
acquired on the ODYSSEY Sa Infrared Imaging System (LI-
COR, Germany).
Maintenance of cell lines
NCI-H661 cells (ATCC #HTB-183) were grown in RPMI-
1640 media (21875-034, Gibco), A549 cells (ATCC # CCL-185)
were grown in Ham’s F-12K (Kaighn’s) media (21127-022,
Gibco), U-251 MG cells (Sigma-Aldrich #09063001) were grown
in DMEM with 4,5 g/l glucose (41965-039, Gibco). All media
were supplemented with penicillin, streptomycin and 10% fetal
calf serum.
Statistical methods
The SPSS 20.0 (Chicago, IL, USA) was used to perform the
statistical analyses.
The Kaplan-Meier method was used for univariate analyses.
The log-rank test was used to test the statistical significance
between survival curves stratified by marker expression.
The endpoint of this study was disease-specific survival (DSS).
DSS was calculated from the time of surgery to the time of lung
cancer death. The cox regression analysis (backward stepwise) was
used to test the independent impact of variables that were
significant in the univariate analyses. In Model 1, MCT1–4 was
tested simultaneously, while in Model 2 co-expression variables
were tested one by one. The significance level for stepwise entry
and removal was set at 0.05 and 0.10 respectively. P = 0.05 was
considered statistically significant for all analyses.
Figure 2. Immunhistochemical staining of MCT1–4 in NSCLC. Low expression: A) MCT1, B) MCT2, C) MCT3, D) MCT4. High expression:
E) MCT1, F) MCT2, G) MCT3, H) MCT4. 1006 and 4006magnification.
doi:10.1371/journal.pone.0105038.g002
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Table 1. Prognostic clinicopathologic variables as predictors of disease-specific survival in 335 NSCLC patients (univariate analyses;
log-rank test).
Characteristics Patients N, (%) Median survival (months) 5-year survival (%) P
Age .42
#65 years 156 (47) 98 56
.65 years 179 (53) NR 60
Sex .22
Female 82 (24) 190 64
Male 253 (76) 98 56
Smoking status .26
Never 15 (5) 19 43
Previous 105 (31) 84 55
Present 215 (64) NR 60
WHO Performance status .016
0 197 (59) NR 63
1 120 (36) 64 52
2 18 (5) 25 33
Weight loss .76
,10% 303 (90) 190 58
.10% 32 (10) 98 57
Histology .028
Squamous cell carcinoma 191 (57) NR 66
Adenocarcinoma 113 (34) 54 46
Large cell carcinoma 31 (9) 98 56
Differentiation ,.001
Poor 138 (41) 47 47
Moderate 144 (43) 190 65
Well 53 (16) NR 68
Surgical procedure 0.007
Wedge + Lobectomy 243 (73) 190 62
Pneumectomy 92 (27) 37 47
p-Stage ,.001
pI 157 (47) NR 72
pII 136 (41) 62 51
pIIIA 42 (12) 17 24
T-status ,.001
1 85 (25) 190 75
2 188 (56) 84 57
3 62 (19) 25 37
N-status ,.001
0 232 (69) NR 67
1 76 (23) 35 43
2 27 (8) 18 18
Surgical margins .37
Free 307 (92) 190 59
Not free 28 (8) 47 48
Vascular infiltration .001
No 284 (85) 190 62
Yes 51 (15) 27 33
NR, not reached.
doi:10.1371/journal.pone.0105038.t001
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Results
Patients characteristics
In Table 1, demographic, clinical and histopathologic variables
are presented. The last DSS update was done in January 2011.
The patients’ median age was 67.1 years (range 28–85) and the
majority of the cohort was male (76%). Ninety-six percent of the
cohort was previous or present smokers. The median follow-up
time of survivors was 99 months (range 9.8–189). The NSCLC
tumors were divided in the following subgroups according to
histology; 191 squamous cell carcinomas (SCC), 113 adenocarci-
nomas (AC) and 31 large-cell carcinomas (LCC).
Expression of hypoxic markers and their correlations
MCT1 and MCT4 expression was mostly membranous, while
MCT2 and MCT3 was mostly cytoplasmic (Figure 2). A moderate
correlation was observed between density of cancer cell expression
of MCT1 and intensity of GLUT1 expression (r = 0.38, P,0.001).
Between clinicopathological factors and MCTs, a moderate
correlation was observed only between density of MCT1 in
cancer cells and histology (r = 0.484, P,0.001) with high
expression in 58% of squamous cell carcinoma compared to
34% in adenocarcinoma.
Univariate analysis
The significant prognostic clinicopathological variables were;
WHO performance status (P = 0.016), histology (P = 0.028),
differentiation (P,0.001), surgical procedure (P = 0.007), p-Stage
(P,0.001), T-status (P,0.001), N-status (P,0.001) and vascular
infiltration (P = 0.001) (Table 1).
Among the metabolic markers examined, qMCT1 expression
in cancer cells (P = 0.021) and qMCT2 (P = 0.006) and qMCT3
(P = 0.020) expression in stromal cells correlated significantly with
a favourable DSS (Table 2 and Figure 3). Whereas qMCT1 in
Figure 3. Kaplan Meier curves with DSS for expression of MCT1 and co-expression variables. Kaplan Meier curves with disease-specific
survival for expression of monocarboxylate transporter (MCT)1 in cancer cells and stromal cells and the co-expression variable GLUT1c+MCT4c and
GLUT1c+MCT1s in NSCLC. A) MCT1 in cancer cells, B) MCT1 in stromal cells, C) GLUT1c+MCT4c, D) GLUT1c+MCT1s.
doi:10.1371/journal.pone.0105038.g003
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stromal cells (P = 0.003) and qMCT4 in cancer cells (P = 0.027)
were significantly associated with a poor DSS. MCT2 and MCT3
in cancer cells and MCT4 in stromal cells had no significant
impact on survival.
The co-expression variables qGLUT1c+qMCT1s (P = 0.001),
qGLUT1c+qMCT4c (P = 0.003) and qMCT4c+qMCT1s
(P = 0.009) were significantly associated with a poor DSS
(Table 3). The co-expression marker qMCT1c+qMCT4s
(P = 0.006) was significantly associated with a positive DSS.
Multivariate analyses
Significant independent prognosticators for poor DSS in the
NSCLC cohort were; T-status .1 (P = 0.002), N-status .0 (P = ,
0.001), moderate differentiation (P = 0.006), QMCT1 in cancer
cells (HR: 1.9, CI 95%: 1.3–2.8, P = 0.001), QMCT2 in stromal
cells (HR: 2.4, CI 95%: 1.5–3.9, P = ,0.001) and QMCT3 (HR:
1.9, CI 95%: 1.1–3.5, P = 0.031), qMCT1 in stromal cells (HR:
1.7, CI 95%: 1.1–2.7, P = 0.016) and the co-expression variables
qGLUT1c+qMCT1s (HR: 7.3, P = 0.016) and qGLUT1c+
qMCT4c (HR: 3.3, P = 0.031) (Table 4).
We tested the PH-assumption (def.: the proportional hazards
assumption; the relative hazard is constant over time, which is a
requirement in the Cox proportional hazards model) for all
markers, and for the MCT1-variable in cancer cells it was violated.
Hence, the follow-up time was split into two intervals (.20
months, #20 months). We chose 20 months because the hazard
Table 2. Monocarboxylate transporters (MCT) 1–4 in cancer and stromal cells as predictors of disease-specific survival in 335
NSCLC patients (univariate analyses; log-rank test).
Characteristics Patients, N (%) Median survival (months) 5-year survival (%) P
MCT1
Cancer cells .021
High 171 (51) NR 66
Low 149 (44) 62 51
Missing 15 (5)
Stromal cells .003
High 201 (60) 71 54




High 220 (66) 127 58
Low 67 (20) NR 64
Missing 48 (14)
Stromal cells .006
High 83 (25) NR 72




High 105 (31) 190 60
Low 192 (58) NR 59
Missing 38 (11)
Stromal cells .020
High 277 (83) 61 190




High 132 (39) NR 51
Low 178 (53) 62 65
Missing 25 (8)
Stromal cells .110
High 165 (49) NR 62
Low 139 (42) 71 53
Missing 31 (9)
doi:10.1371/journal.pone.0105038.t002
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was proportional past this point. We then performed a separate
Cox regression analysis and the results were as follows: HR (total):
1.9, HR(.20 months): 2.3, HR(#20 months): 0.9.
Discussion
We present the first large-scale study on the prognostic role of
MCT1–4 in both cancer cells and cells of the tumor stroma in
NSCLC. Our main finding is that qMCT1 expression in cancer
and stromal cells has a significant, independent impact on disease-
specific survival, but with contrary effects in the two investigated
compartments. qMCT1 in cancer cells is an independent positive
prognostic factor. qMCT1 in stromal cells is an independent
negative prognosticator. In addition, qGLUT1c+qMCT1s and
qGLUT1c+qMCT4c show a substantial synergetic and inde-
pendent impact on DSS when compared to low expression of these
markers.
Our study confirms the presence of MCT1, MCT2 and MCT4
in NSCLC cancer cells and stromal cells, in agreement with the
study by Koukourakis et al.[12]. To our knowledge, this is the first
report on MCT3 being expressed in both cancer and stromal cells
in NSCLC. We also show that MCT1 and MCT4 are located in
the cell membrane, whereas MCT2 and MCT3 are expressed in
the cytosol of NSCLC cells. The latter is in support of MCT2’s
hypothesized role in import of pyruvate in the mitochondria [11].
Besides, the specificity of the MCT1 and MCT4 antibodies was
confirmed by Western blot, providing additional evidence for the
validity of our main findings.
The association between qMCT1 expression in NSCLC
cancer cells and improved survival was unexpected. Fang et al.
reported in 2006 an elevated MCT1 mRNA expression to be
correlated with a negative prognosis in neuroblastomas [16]. But
apart from this study, a negative prognostic impact of MCT has
only been demonstrated when MCT1 is co-expressed with CD147
or p53 [17–19]. Halestrap et al. reports that MCT1 is capable of
transporting lactate both in and out of the cell, and that the
direction of lactate transport is dependent on the pH-gradient
[10]. And so, an explanation for our contrasting finding may be
that MCT1 is transporting lactate in an opposite direction in
neuroblastomas compared to NSCLC. MCT1 in NSCLC cancer
cells may import lactate, while in neuroblastoma MCT1 exports
lactate. In support of this, Chen et al. reported that lactate, likely
imported by MCT1, can induce a certain gene expression profile
in breast cancer, associated with a beneficial clinical outcome [20].
Some of these genes favored oxidative phosphorylation. For cells
to be able to utilize lactate imported by MCT1, as a metabolic
fuel, they must have oxygen available to enable oxidative
phosphorylation and thereby ATP production. We hypothesize
that qMCT1 expression in NSCLC cancer cells serve as a
positive prognostic factor, because its expression indicates an
overall less aggressive oxidative/metabolic cancer phenotype in
NSCLC. However, functional studies are warranted to clarify
MCT1’s impact in NSCLC, since Izumi et al. stated that MCT1,
together with MCT4, may promote cancer cell invasion in lung
cancer [21].
Our data show that qMCT1 expression in stromal cells of the
tumor is a negative prognostic factor in NSCLC, which is
consistent with the finding of Sonveaux et al. [22]. They observed
MCT1 expressed in endothelial cells to be involved in tumor
angiogenesis activation. In their study, lactate activated the
transcription factor HIF1a in endothelial cells, which promoted
the expression of bFGF and VEGFR2. Vegran et al. state that
lactate from cancer cells, exported by MCT4 and imported by
MCT1 in endothelial cells, consecutively stimulate angiogenesis
Table 3. Metabolic co-expression variables in cancer and stromal cells as predictors of disease-specific survival in 335 NSCLC
patients (univariate analyses; log-rank test).
Co-expression variables Patients N (%) Median survival (months) 5-year survival (%) P
GLUT1c+MCT1s .001
Low/Low 25 NR 91
Other 114 190 63
High/High 161 64 51
Missing 35
GLUT1c+MCT4c .003
Low/Low 31 NR 82
Other 170 190 62
High/High 101 52 48
Missing 33
MCT4c+MCT1s .009
Low/Low 72 NR 74
Other 129 98 58
High/High 97 57 50
Missing 37
MCT1c+MCT4s .006
Low/Low 81 62 51
Other 114 62 51
High/High 106 NR 72
Missing 34
doi:10.1371/journal.pone.0105038.t003
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through NF-kB and IL-8 signalling [23]. In addition, Rattigan et
al. found that lactate can induce MCT1 expression in mesenchy-
mal cells, and in turn contribute to a metabolic co-operation of
lactate homeostasis between recruited stromal cells and glycolytic
cancer cells, which also is in agreement with our results [24].
Our data demonstrate that the ability to predict survival in
NSCLC patients is substantially improved when we combine the
key metabolic markers GLUT1 and MCT4, and GLUT1 and
MCT1. Our study confirms that qGLUT1c+qMCT4c has a
negative prognostic impact in NSCLC, in agreement with the
results of Meijer et al. [25]. However, they made their observation
only in adenocarcinomas, while we found the same trend in all
histological subgroups of NSCLC. This is most likely due to the
fact that our NSCLC cohort is considerable larger than that of
Meijer et al. To our knowledge, this is the first study reporting that
co-expression of qGLUT1c+qMCT1s has a significant syner-
getic, negative prognostic impact. This result is interesting, since it
provides strong additional evidence of the theory of Koukourakis
Table 4. Results of Cox regression analyses (backward stepwise model) for clinicopathological factors and monocarboxylate
transporters (MCTs) (model 1) and metabolic co-expression variables (*model 2).
Model 1 All patients N = 335
Factor HR CI 95% P
T-status .002
T1 1(ref)
T2 1.6 (0.95–2.7) .079
T3 2.8 (1.6–5.1) .001
N-status .000
N0 1(ref)
N1 2.0 (1.3–3.2) .002




Poor 1.4 (0.74–2.7) .306
WHO PS NS NS NS
Vascular infiltration NS NS NS
Histology NS NS NS
MCT1 Cancer cellsTotal* .001
Low 1.9 (1.3–2.8)
High 1(ref)
MCT1 Stromal cells .016
Low 1(ref)
High 1.7 (1.1–2.7)
MCT2 Stromal cells .000
Low 2.4 (1.5–3.9)
High 1(ref)
MCT3 Stromal cells .031
Low 1.9 (1.1–3.5)
High 1(ref)
MCT4 Cancer cells NS NS NS
MCT4c+MCT1s* NS NS NS
MCT1c+MCT4s* NS NS NS
GLUT1c+MCT1s* .016
Low/low 1(ref)
Other 5.8 (1.4–24.4) .016
High/high 7.3 (1.8–30.3) .006
GLUT1c+MCT4c* .031
Low/low 1(ref)
Other 2.4 (.94–6.4) .068
High/high 3.3 (1.2–3.3) .016
doi:10.1371/journal.pone.0105038.t004
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et al. [11,12]. They hypothesized that stromal cells of the tumor is
an accomplice in tumor growth and survival, by enabling cancer
cells to maintain high glycolytic metabolism (qGLUT1) by
utilizing the by-product of glycolysis; lactate (qMCT1 in stromal
cells).
Cancer metabolism is regarded as a promising target for cancer
therapy, and inhibition of MCT1 in cancer cells and in endothelial
cells has been suggested as a potential target. So, is MCT1 a
potential therapeutic target in NSCLC in light of our result?
Despite being a positive prognostic marker when expressed in
cancer cells, inhibition of MCT1 in NSCLC cancer cells will
possibly not affect these less aggressive cells directly. Busk et al.
report that inhibition of MCT1 leads to indirect starving of latent
malignant hypoxic cancer cells that are present in the heteroge-
nous tumor [26]. On the other hand, inhibition of MCT1 in
cancer cells may be contraindicated since lactate import is thought
to induce expression of a less aggressive gene expression profile
[20]. Our data show that qMCT1 in stromal cells is a negative
prognostic factor. Selective inhibition of MCT1 in stromal cells is a
potential target strategy and inhibition of MCT1 in endothelial
cells has already been suggested [22].
This is the first large-scale study on the prognostic role of
MCT1–4 in NSCLC. The results presented herein demonstrate
that MCT1 play crucial, but apparently opposing roles in cancer
cell versus stromal cell compartments. We propose MCT1 as a
new prognostic marker in NSCLC, although expression in cancer
cells versus stromal cells mediates opposing prognostic impacts.
Metabolic targeting is still largely an unexploited opportunity in
cancer treatment more than 80 years after Warburg’s ground-
breaking studies. As MCTs are pivotal molecular effectors in
tumor metabolism they serve as promising therapeutic targets. As
there are contrasting prognostic impacts in cancer cells versus
stromal cells, attention must be given to their role according to
tumor compartments in future functional and expression analysis
studies.
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